Home » Clinical Trials » Solid tumors » NCT05583201
NCT05583201

A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors

Study Summary

This is a Phase 1, single-arm, single-center, open-label study to evaluate the safety and effectiveness of NKG2D/CLDN18.2-based CAR-T cells infusion in the treatment of advanced NKG2DL+/CLDN18.2+ solid tumors.

Want to learn more about this trial?

Request More Info

Interventions

KD-496BIOLOGICAL
Autologous genetically modified anti-NKG2DL/CLDN18.2 CAR transduced T cells

Study Locations

FacilityCityStateCountry
Chinese PLA General HospitalBeijingChina

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: April 14, 2026